A Phase I Clinical Study of TQB3002 in Patients With Advanced Cancers
Latest Information Update: 05 Nov 2024
Price :
$35 *
At a glance
- Drugs TQB 3002 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 05 Nov 2024 New trial record